JP2003524592A5 - - Google Patents

Download PDF

Info

Publication number
JP2003524592A5
JP2003524592A5 JP2000557816A JP2000557816A JP2003524592A5 JP 2003524592 A5 JP2003524592 A5 JP 2003524592A5 JP 2000557816 A JP2000557816 A JP 2000557816A JP 2000557816 A JP2000557816 A JP 2000557816A JP 2003524592 A5 JP2003524592 A5 JP 2003524592A5
Authority
JP
Japan
Prior art keywords
coating
protective
protective coating
soluble
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000557816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003524592A (ja
Filing date
Publication date
Priority claimed from US09/111,188 external-priority patent/US5968554A/en
Priority claimed from US09/338,716 external-priority patent/US6312728B1/en
Application filed filed Critical
Publication of JP2003524592A publication Critical patent/JP2003524592A/ja
Publication of JP2003524592A5 publication Critical patent/JP2003524592A5/ja
Pending legal-status Critical Current

Links

JP2000557816A 1998-07-07 1999-06-25 持続放出薬物製剤 Pending JP2003524592A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/111,188 US5968554A (en) 1998-07-07 1998-07-07 Sustained release pharmaceutical preparation
US09/111,188 1998-07-07
US09/338,716 1999-06-23
US09/338,716 US6312728B1 (en) 1998-07-07 1999-06-23 Sustained release pharmaceutical preparation
PCT/US1999/014204 WO2000001369A1 (en) 1998-07-07 1999-06-25 Sustained release pharmaceutical preparation

Publications (2)

Publication Number Publication Date
JP2003524592A JP2003524592A (ja) 2003-08-19
JP2003524592A5 true JP2003524592A5 (https=) 2006-01-05

Family

ID=26808709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000557816A Pending JP2003524592A (ja) 1998-07-07 1999-06-25 持続放出薬物製剤

Country Status (10)

Country Link
US (1) US6312728B1 (https=)
EP (1) EP1094790B9 (https=)
JP (1) JP2003524592A (https=)
AT (1) ATE274344T1 (https=)
AU (1) AU5084299A (https=)
CA (1) CA2337046C (https=)
DE (1) DE69919713T2 (https=)
ES (1) ES2226412T3 (https=)
IL (1) IL140761A0 (https=)
WO (1) WO2000001369A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US6572889B1 (en) 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US20040043067A1 (en) * 2002-06-19 2004-03-04 Salamone Joseph C. Fluorosiloxane matrix controlled diffusion drug delivery systems
PA8578501A1 (es) 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
CA2501324A1 (en) * 2002-10-30 2004-05-21 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
WO2005030179A1 (en) * 2003-09-29 2005-04-07 Cj Corporation Sustained-release formulations
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
WO2005117697A2 (en) * 2004-05-28 2005-12-15 Narayanan Ramasubramanian Unified indigestion package and process for patient compliance with prescribed medication regimen
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
CN101022788B (zh) 2004-08-13 2010-11-10 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
UA93608C2 (ru) 2004-08-13 2011-02-25 Берингер Ингельхайм Интернациональ Гмбх композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
CA2642275A1 (en) 2006-02-13 2007-08-23 Vanda Pharmaceuticals, Inc. Stable dosage formulations of imidazolylalkyl-pyridines
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
DK2152250T3 (da) * 2007-05-07 2019-12-09 Evonik Degussa Gmbh Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse
EP2222301B1 (en) 2007-12-13 2014-10-08 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
WO2009076664A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
AR122353A1 (es) 2019-12-27 2022-09-07 Evelo Biosciences Inc Formas farmacéuticas sólidas que contienen bacterias y vesículas extracelulares microbianas
WO2021146523A1 (en) 2020-01-17 2021-07-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
JP2023522018A (ja) 2020-04-17 2023-05-26 エヴェロ バイオサイエンシズ,インコーポレーテッド 改善された崩壊プロファイルを有する固形剤形
MX2023003089A (es) 2020-09-18 2023-05-09 Evelo Biosciences Inc Formas farmaceuticas solidas de bacterias.
TW202233213A (zh) 2020-10-29 2022-09-01 美商艾弗洛生物科技股份有限公司 包含螺旋藻組分之組成物
US20240058271A1 (en) 2020-12-14 2024-02-22 Kevin Huynh Extracellular vesicle preparations
EP4267154A1 (en) 2020-12-22 2023-11-01 Evelo Biosciences, Inc. Compositions comprising animal hemoglobin
JP2024505207A (ja) 2021-01-26 2024-02-05 エヴェロ バイオサイエンシズ,インコーポレーテッド プレボテラ(Prevotella)細胞外小胞調製物
US20240148797A1 (en) 2021-02-26 2024-05-09 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187578A1 (en) 2021-03-05 2022-09-09 Evelo Biosciences, Inc. Solid dosage forms
TW202304415A (zh) 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
WO2022221183A1 (en) 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
KR20240093504A (ko) 2021-09-24 2024-06-24 에벨로 바이오사이언시즈, 인크. 박테리아 및 미생물 세포외 소포를 함유하는 고체 투여 형태
WO2023114300A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114295A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
WO2023114293A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle assays
WO2023146843A1 (en) 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023183396A1 (en) 2022-03-22 2023-09-28 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023200837A1 (en) 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023239728A1 (en) 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
WO2024102226A1 (en) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994260A (en) 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
ATE114472T1 (de) * 1989-09-21 1994-12-15 American Cyanamid Co System des typs ''einmal täglich'' zur gepulsten minocyclinabgabe.
EP0497977B1 (en) * 1989-10-26 1995-03-15 Nippon Shinyaku Company, Limited Gastric preparation
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US5968554A (en) * 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation

Similar Documents

Publication Publication Date Title
JP2003524592A5 (https=)
CA2213996A1 (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
CA2323680A1 (en) Orally disintegrable tablets
JP2005516946A5 (https=)
JPH1072351A5 (https=)
EP1420777A4 (en) PHARMACEUTICAL COMPOSITIONS WITH BETA-LAPACHONE OR DERIVATIVES OR ANALOGUE THEREOF AND METHOD FOR THEIR USE
TW476777B (en) Abrasive liquid for metal and method for polishing
MA26516A1 (fr) Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant.
CA2348451A1 (en) Dosage forms containing taste masked active agents
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
TNSN01123A1 (fr) Formes posologiques nouvelles a liberation controlee
ATE473006T1 (de) Beschichtete teilchenförmige cefuroximeaxetil- zusammensetzungen
EP1534327A4 (en) METHOD FOR THE TREATMENT AND PREVENTION OF RSV, HMPV, AND PIV WITH ANTI-RSV, ANTI-HMPV AND ANTI-PIV ANTIBODIES
CA2387873A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
EP1123696A4 (en) PREPARATIONS FOR THE MOUTH
CA2338794A1 (en) New oral formulation for 5-ht4 agonists or antagonists
WO2001034137A3 (en) Oncolytic combinations for the treatment of cancer
EP1181931A3 (en) Intraoral adhesive preparation
JP2005509503A5 (https=)
JP2005519863A5 (https=)
NO20021640D0 (no) Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Ginko Biloba
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
HUP9901873A3 (en) Benzisoxazole and benzisoxazolidinone derivatives, preparation of the latter, herbicide compositions containing these compounds and use thereof